Inspyr Therapeutics, Inc.: Inspyr Therapeutics Further Strengthens Global Intellectual Property
WESTLAKE VILLAGE, CA / ACCESSWIRE / February 18, 2021 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, announces additional expansion of its global intellectual property portfolio of adenosine receptor antagonists in China, Eurasia, and Israel.
Management continues to execute on the expansion that further provides flexibility to pursue novel treatments based on the specific targets found in multiple types of cancer in different demographics. The issued Eurasia patent and soon to issue Chinese and Israeli patents strengthen the company s global intellectual property portfolio. Per the announcement in December of 2020, 18 patents have already been issued in its intellectual portfolio in potential future commercial markets including the United States, Europe, th
Inspyr Therapeutics Further Strengthens Global Intellectual Property
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Inspyr Therapeutics Further Strengthens Global Intellectual Property
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
Inspyr Therapeutics Further Strengthens Global Intellectual Property
phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
E-Mail
WASHINGTON - Pancreatic cancer, one of the most lethal of all cancers, is capable of evading attacks by immune cells by changing its microenvironment so that the immune cells suppress, rather than support, an attack on the tumor. The scientists also found that that some of the mediators of this suppressive response, including a protein called STAT1, represent potential therapeutic targets that could be used to reverse this evasion and point to possible treatment opportunities.
The finding appears January 28, 2021, in
Cancer Immunology Research. This is the first demonstration that an immune attack induces pancreatic cancer-derived immune suppression, offering a new approach to immunotherapy for this deadly cancer, noted Louis M. Weiner, M.D., director of Georgetown Lombardi and the Principal Investigator of this study.